Members

Almirall

We bring Science to you. We create powerful therapeutic solutions through our strong commitment to R&D within key areas, focusing our innovation at every point in the pharmaceutical value chain. A consolidated profitable growth gives us the opportunity to devote our talent and efforts towards speciality areas and particularly in helping to treat all major skin diseases through our advances in dermatology.

For more information, please visit: www.almirall.com.

argenx

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases and cancers by translating immunology breakthroughs into potential new medicines. argenx has offices in Belgium, the United States, Japan, Switzerland, the United Kingdom and Italy.

For more information, please visit: www.argenx.com.

Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with our mission, “Health for all, Hunger for none,” our products and services are designed to help people and the planet thrive by supporting efforts to overcome the major challenges presented by a growing and aging global population. At Bayer UK, we are dedicated to developing healthcare solutions that benefit patients, the NHS, and the clinical community through ongoing research and partnerships aimed at maximising clinical value and advancing treatment approaches in the fields of Cardiovascular, Women’s Health, Ophthalmology, Oncology and Radiology. In the UK and Ireland, Bayer employs approximately 900 people across three divisions: Pharmaceuticals, Crop Science and Consumer Health. In fiscal 2023, the UKI group reported sales of approximately 1 billion euros, with UK R&D investments totalling £45 million.

For more information, please visit: www.bayer.co.uk

BeOne

BeOne Medicines is a global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning haematology and solid tumours, BeOne is expediting development of novel therapeutics through its internal capabilities and collaborations. Our nearly 12,000 colleagues are driven by scientific excellence and exceptional speed to reach more patients than ever before.

For more information, please visit: www.beonemedicines.co.uk.

Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

For more information, please visit: www.boehringer-ingelheim.co.uk

Chiesi

Based in Parma, Italy, Chiesi Farmaceutici S.p.A is an international, privately-owned Healthcare Group, with over 80 years of experience in the pharmaceutical industry and over 4,800 employees. We are dedicated to the research, development, production and commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care therapeutic areas. Present in 26 countries, Chiesi’s largest markets (based on direct sales) are the USA, the UK, Germany and France.

For more information, please visit: www.chiesi.com

CSL Vifor

CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease. CSL Vifor strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company researches, develops, manufactures and markets targeted products for patients. Headquartered in St.Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

The parent company, CSL headquartered in Melbourne, Australia, employs 30,000 people and delivers its therapies to people in more than 100 countries. 

For more information, please visit: www.viforpharma.com/uk

Job number: UK-NP-2200081      Date of prep: October 2022

Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

For more information, please visit: www.ferring.com

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external innovation strategy, the Company’s research and development efforts are focused on innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.. Ipsen has around 5,700 colleagues worldwide and is listed in Paris (Euronext: IPN). In the UK Ipsen employs 750 people across three sites, Research & Development (Abingdon, Oxford), Pharmaceutical Development and Manufacturing (Wrexham, Wales) and Commercial headquarters (Slough, Berkshire).

For more information, please visit: www.ipsen.com/uk

Jazz

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We actively explore new options for patients including novel compounds, small molecules and biologics, and through cannabinoid science and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries.

For more information, please visit: www.jazzpharma.com.

LEO

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of EUR 1,430 million.

For more information, please visit: www.leo-pharma.co.uk

Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

For more information, please visit: www.lundbeck.com

Menarini

Founded in 1886, Menarini Group are a privately-owned, family run business headquartered in Florence, Italy.  Menarini are the leading Italian pharmaceutical company in the world. Menarini pursue two core strategic objectives Research and Internationalisation.  Our commitment to the development of new medicines and therapeutic indications has consolidated our role as the partner for excellence in the pharmaceutical and biotechnology fields. Menarini employ over 17,000 people worldwide, 91% of which hold degrees or diplomas.  One of Europe’s 20 largest producers of pharmaceutical specialities. Menarini ranks 17^th among pharmaceutical Companies in Europe.  With an annual turnover of €3 billion, Menarini is one of the 100 largest European companies.

For more information, please visit: www.menarini.com

Merck

We are Merck UK, a vibrant science and technology company rooted in science and innovative research. Merck has eleven life sciences sites across the UK, employing over 1,800 individuals. In our healthcare division we focus on personalised solutions for unmet medical needs in our key therapy areas; Oncology, Neurology & Immunology and Fertility.

Merck is the oldest pharmaceutical company in the world and we have been curious for generations. Since our company was founded in 1668, we have always pushed ourselves to go further, and for our family to do more for your family. At Merck, curiosity and a spirit of discovery make us who we are, and who we always have been.

Merck has been collaborating for generations to tackle some of the world’s most challenging diseases, working hand in hand with the scientific community, the NHS and policy-makers to ensure patients have access to the treatments they need. Brilliant ideas are born at Merck. We have been innovating for generations to support people at every stage of life. From ground-breaking treatments for conditions including cancer and multiple sclerosis (MS), to fertility medicines that help spread the joy of birth, we help millions of people every day.

Merck has been a family for generations. Even with our considerable growth, the founding family remains the majority owner of the company – and that family heritage anchors our ethical approach to our employees, our partnerships, the environment and the wider world. We understand that at some point in our lives we will all be a patient, and our Merck family is here for yours.

For more information, please visit: www.merckgroup.com

Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Its commitment to transforming people’s lives drives everything it does and its European experience, fully integrated infrastructure and exceptional partnership approach enables it to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2019.

Norgine has a direct presence in 12 European countries, as well as Australia and New Zealand. It also has a global network of partnerships in non-Norgine markets. In the UK, Norgine employs around 850 people across two sites:

• Harefield site: This site houses several of Norgine’s global functions and Norgine’s UK Sales and Marketing operations. The site employs around 320 staff.
• Hengoed site: In Wales, Norgine makes a considerable contribution to the growth of the life sciences sector. Norgine employs over 500 staff in Wales and is the largest pharmaceutical employer. Norgine has been researching and manufacturing innovative medicines in Hengoed since 1969 to improve the lives of millions of patients around the world. Manufacturing takes place 24 hours a day, 7 days a week to supply over 30 million packs of medicines every year. Norgine’s Hengoed site has won an RoSPA gold award for their approach to health and safety for the last five years in a row.

For more information, please visit: www.norgine.com. Follow us on Twitter @Norgine.

Novartis

Novartis is a global pharmaceutical employing 104,000 people, 45% in R&D and manufacturing roles. Novartis has a portfolio and pipeline of medicines treating cardiovascular disease, cancer, immunology driven conditions, alongside advanced therapeutic platforms such as gene therapies and radioligand therapy. Novartis has also supplied over 1 billion doses of malaria treatments to the developing world, most without profit and is committed to net zero across its operations by 2040.

For more information, please visit: www.novartis.co.uk

Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries.

For more information, please visit: www.novonordisk.co.uk

Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.  Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

For more information, please visit: www.roche.com

Sanofi

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

For more information, please visit: www.sanofi.co.uk

Servier

Servier is an international pharmaceutical company governed by a non‐profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 150 countries, 16 production sites, 15 International Centers for Therapeutic Research, 6 research centers and 1 network for external innovation, Servier generated €4.7 billion revenues in 2020/2021. Servier employs 21,800 people worldwide. Entirely independent, the Group reinvests 20% of its revenues (excluding generic drugs) in research and development and uses all its profits for development. 98% of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France. Corporate growth is driven by Servier’s constant search for innovation in 4 therapeutic areas: oncology, cardiometabolism, neuroscience and immuno-inflammation.

For more information, please visit: www.servier.com.

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases.  We are driven by our passion to help people with rare diseases live the life they want.  We specialise in treatments across Haematology, Immunology and Specialty Care, including for haemophilia A, haemophilia B, haemo-oncology, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP) and other rare immune conditions.  With decades of experience across the UK, our heritage means we have specialist insight which enables us to provide treatments and support that can transform the lives of people with rare diseases and those that care for them, both now and for many generations to come.

For more information, please visit: www.sobi.com/uk

UCB

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,600 people in approximately 40 countries, the company generated revenue of €5.8 billion in 2021.

For more information, please visit: www.ucb.com